Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
Trial details
- Registry ID
- NCT05925127
- Phase
- Phase 2, Phase 3
Drug identity checked against registry records
Also recorded as Omicron Subvariant/Prototype Licensed mRNA Vaccine
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS VaccinesNCT05925127 | Novavax | Phase 2, Phase 3 | Completed | 2024-05-21Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |